Editas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting
Oral presentation of first achievement of in vivo retinal gene editing in non-human primates
Oral presentation of results demonstrating the potential of CRISPR/Cas9 gene editing to treat sickle cell disease and beta-thalassemia
Key
- First report of results from in vivo gene editing of inherited retinal disease genes in non-human primates;
- CRISPR/Cas9-mediated editing and engraftment of hematopoietic stem cells preclinically for the treatment of β-hemoglobinopathies;
- Self-inactivating Cas9: A proprietary approach for controlling exposure while maintaining efficacy in virally-delivered Cas9 applications; and
- UDiTaS™: A proprietary genome editing analytical method to comprehensively characterize multiple forms of editing, including on- and off-target edits, large deletions, and translocations.
In addition, Editas scientists will be chairing sessions on cardiovascular and pulmonary gene and cell therapies, on AAV vector systems, and a scientific symposium on getting cures to patients.
“Editas Medicine is at the forefront of the rapidly-advancing science that is unlocking the potential of CRISPR for patients,” said
The complete list of
Oral Presentations:
Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice
Date/Time:
Location:
Session: Genome Editing and Integration Analysis in Metabolic and Endocrine Disorders
CRISPR/Cas9-mediated Editing of Hematopoietic Stem Cells for the Treatment of β-Hemoglobinopathies
Date/Time:
Location:
Session: Therapeutic Editing of the Human Genome and Epigenome
Efficient In Vivo Gene Editing of Inherited Retinal Disease Genes in Mice and Non-Human Primates
Date/Time:
Location: Thurgood Marshall North
Session: Preclinical Progress Towards Therapies for Neurosensory Disorders
Poster Presentations:
Characterization of Targeted Integration with Viral and Non-Viral DNA Donors
Date/Time:
Location: Exhibit Hall A & B South
Session: Gene Targeting and Gene Correction II
Self-inactivating Cas9: A method for Reducing Exposure While Maintaining Efficacy in Virally-delivered Cas9 Applications
Date/Time:
Location: Exhibit Hall A & B South
Session: Gene Targeting and Gene Correction II
UDiTaS™: A Streamlined Genome Editing Detection Method for On- and Off-target Edits, Large Deletions, and Translocations
Date/Time:
Location: Exhibit Hall A & B South
Session: Gene Targeting and Gene Correction III
About Editas Medicine
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “would,” similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the
Contacts Media:Cristi Barnett (617) 401-0113 cristi.barnett@editasmed.com Investors:Mark Mullikin (617) 401-9083 mark.mullikin@editasmed.com